A detailed history of Whittier Trust CO Of Nevada Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Whittier Trust CO Of Nevada Inc holds 576 shares of VRTX stock, worth $259,413. This represents 0.01% of its overall portfolio holdings.

Number of Shares
576
Previous 551 4.54%
Holding current value
$259,413
Previous $258,000 3.49%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 21, 2024

BUY
$460.0 - $505.78 $11,500 - $12,644
25 Added 4.54%
576 $267,000
Q2 2024

Jul 26, 2024

SELL
$392.81 - $485.53 $10,998 - $13,594
-28 Reduced 4.84%
551 $258,000
Q1 2024

May 02, 2024

BUY
$407.69 - $446.08 $7,338 - $8,029
18 Added 3.21%
579 $242,000
Q4 2023

Jan 11, 2024

SELL
$343.0 - $410.68 $103,243 - $123,614
-301 Reduced 34.92%
561 $228,000
Q3 2023

Oct 27, 2023

SELL
$338.18 - $362.46 $1,690 - $1,812
-5 Reduced 0.58%
862 $299,000
Q2 2023

Jul 24, 2023

SELL
$314.42 - $351.91 $1,257 - $1,407
-4 Reduced 0.46%
867 $305,000
Q1 2023

Apr 21, 2023

BUY
$283.23 - $323.1 $105,644 - $120,516
373 Added 74.9%
871 $274,000
Q4 2022

Jan 25, 2023

SELL
$285.76 - $321.48 $97,158 - $109,303
-340 Reduced 40.57%
498 $0
Q3 2022

Oct 21, 2022

BUY
$273.83 - $305.53 $86,256 - $96,241
315 Added 60.23%
838 $243,000
Q2 2022

Jul 28, 2022

SELL
$234.96 - $292.55 $22,556 - $28,084
-96 Reduced 15.51%
523 $147,000
Q4 2021

Jan 19, 2022

SELL
$177.01 - $223.45 $5,664 - $7,150
-32 Reduced 4.92%
619 $136,000
Q3 2021

Nov 01, 2021

BUY
$181.39 - $202.99 $66,388 - $74,294
366 Added 128.42%
651 $118,000
Q3 2017

Oct 23, 2017

BUY
$148.13 - $162.24 $42,217 - $46,238
285
285 $43,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Whittier Trust CO Of Nevada Inc Portfolio

Follow Whittier Trust CO Of Nevada Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Whittier Trust CO Of Nevada Inc, based on Form 13F filings with the SEC.

News

Stay updated on Whittier Trust CO Of Nevada Inc with notifications on news.